LinkedIn Profile

Access Enterin historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:enterininc 11060488 Nov 18th, 2019 12:00AM Enterin Inc. 343 18.00 Open Biotechnology Nov 18th, 2019 04:13PM Nov 18th, 2019 04:13PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 17th, 2019 12:00AM Enterin Inc. 343 18.00 Open Biotechnology Nov 17th, 2019 04:38PM Nov 17th, 2019 04:38PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 16th, 2019 12:00AM Enterin Inc. 343 18.00 Open Biotechnology Nov 16th, 2019 04:32PM Nov 16th, 2019 04:32PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 15th, 2019 12:00AM Enterin Inc. 342 18.00 Open Biotechnology Nov 15th, 2019 01:12PM Nov 15th, 2019 01:12PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 13th, 2019 12:00AM Enterin Inc. 341 18.00 Open Biotechnology Nov 13th, 2019 01:34PM Nov 13th, 2019 01:34PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 12th, 2019 12:00AM Enterin Inc. 339 18.00 Open Biotechnology Nov 12th, 2019 03:15PM Nov 12th, 2019 03:15PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 11th, 2019 12:00AM Enterin Inc. 338 18.00 Open Biotechnology Nov 11th, 2019 03:13PM Nov 11th, 2019 03:13PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 10th, 2019 12:00AM Enterin Inc. 338 18.00 Open Biotechnology Nov 10th, 2019 06:20PM Nov 10th, 2019 06:20PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 9th, 2019 12:00AM Enterin Inc. 336 18.00 Open Biotechnology Nov 9th, 2019 05:47PM Nov 9th, 2019 05:47PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin
private:enterininc 11060488 Nov 8th, 2019 12:00AM Enterin Inc. 335 18.00 Open Biotechnology Nov 8th, 2019 02:59PM Nov 8th, 2019 02:59PM Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinson’s Disease and other neurodegenerative conditions. Open Gut-brain axis, Parkinson’s Disease, Neurodegenerative disease, Enteric nerve system, ENT-01 Open Philadelphia PA US Enterin

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.